Table 2

 Clinical variables at baseline and 6-month changes (estimated marginal means) after adjustments for the baseline value and the propensity score

Baseline6-month changes
MTX (n = 380)Anti-TNF (n = 146)p-value*MTX (n = 356)Anti-TNF (n = 132)p Value*
Values are presented as mean (standard deviation of the mean). ESR, erythrocyte sedimentation rate; SJC, Swollen joint count (28 joints); TJC, tender joint count (28 joints); VAS, visual analogue scale; DAS, disease activity score; M-HAQ, modified health assessment questionnaire; SF-6D, short form 6D.
*p-value for anti-TNF compared to MTX.
ESR23.6 (20.1)30.4 (28.1)0.01−6.7 (14.4)−16.3 (12.5)<0.001
SJC4.9 (4.4)4.9 (4.8)0.97−2.1 (3.3)−2.1 (3.8)0.91
TJC6.3 (5.6)7.5 (7.0)0.08−2.3 (3.1)−2.7 (6.2)0.57
VAS fatigue46.7 (28.5)56.8 (25.3)<0.001−0.4 (27.3)−12.7 (32.1)0.001
VAS pain48.3 (22.0)53.5 (22.4)0.02−9.6 (23.3)−21.6 (27.4)<0.001
VAS patient’s global52.2 (21.0)58.1 (21.3)<0.01−11.6 (23.2)−22.7 (27.3)<0.001
DAS-284.5 (1.2)4.8 (1.4)0.02−0.8 (1.3)−1.7 (1.6)<0.001
M-HAQ1.64 (0.45)1.83 (0.47)<0.001−0.16 (0.4)−0.30 (0.5)0.01
SF-36:
    Physical function53.0 (22.8)42.3 (21.6)<0.0016.8(21.8)12.3(25.7)0.06
    Role (physical)21.6 (32.5)12.5 (25.3)0.00111.9(38.9)25.6(45.8)0.01
    Bodily pain32.9 (16.5)29.1 (17.0)0.0210.2(20.1)17.8(23.6)0.01
    General health50.3 (20.3)40.0 (16.8)<0.0012.0(19.4)7.0(22.8)0.03
    Vitality40.6 (22.4)30.8 (20.0)<0.0015.2(20.7)12.0(24.3)0.01
    Social function65.3 (26.3)56.7 (24.2)0.0017.1(23.6)9.0(27.8)0.56
    Role (mental)50.8 (42.2)52.2 (43.8)0.7410.0(40.0)9.9(47.0)0.98
    Mental health71.2 (18.6)70.0 (18.0)0.392.6(15.2)4.7(17.8)0.30
SF-6D0.57 (0.10)0.55 (0.09)<0.010.040 (0.10)0.066 (0.11)0.07